ARCUTIS BIOTHERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 27 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $130M | ↑+81.5% | — | — | — |
| 2025-09-30 | $99M | ↑+121.7% | $7M | ↑+117.8% | 8.6% |
| 2025-06-30 | $82M | ↑+164.1% | $-16M | ↑+69.6% | -17.9% |
| 2025-03-31 | $66M | ↑+32.8% | $-25M | ↑+29.2% | -37.3% |
| 2024-12-31 | $71M | ↑+427.6% | — | — | — |
| 2024-09-30 | $45M | ↑+17.4% | $-42M | ↑+7.2% | -87.3% |
| 2024-06-30 | $31M | ↑+494.6% | $-52M | ↑+26.3% | -162.3% |
| 2024-03-31 | $50M | ↑+1682.4% | $-35M | ↑+55.8% | -63.8% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$130M
↑+81.5% +$58M YoY
Net Income
$15M
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ARQT Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyARQT Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics